Cell BioEngines
'Off-the-shelf' Curative Cell Therapies
* Data source: Crunchbase
- Founded
- 2022
- Employees*
- 2-10
- Funding to Date*
- $525,000
- Website
- cellbioengines.com
"In the future, next-generation cell therapies for cancer will be available ‘off-the-shelf’ as ‘drugs’ with discrete controlled phenotype or state driving consistent anticancer functions.”
Cell-based immunotherapy in cancer has shown a game-changing improvement demonstrating 60% of patients in complete remission after 5 years of treatment.
Cell BioEngines is a US-based clinical-stage biotechnology company pioneering off-the-shelf, allogeneic cell therapies. Leveraging stem cells from highly compatible super-donors and powered by its proprietary STEM-Space platform, the company delivers scalable cell products with reduced risk of immune rejection.
Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free manufacturing platform enabled by advanced biological/chemical programming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage.